Yorktown Management & Research Company’s Arcutis Biotherapeutics ARQT Stock Holding History

Yorktown Management & Research Company’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$420K	Buy	+16,000	New	+$373K	0.26%	148

Other funds holding ARQT

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

JAFL

Jay A. Fishman Ltd Troy, Michigan $1.26B AUM 31.39% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

Yorktown Management & Research Company's ARQT Position: Q2 2026 in Review

Yorktown Management & Research Company opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 16,000 shares worth $420K. The stake represents 0.26% of the portfolio and ranks #148 among its holdings.

63 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Yorktown Management & Research Company held 16,000 shares of Arcutis Biotherapeutics worth $420K as of Q2 2026.
Arcutis Biotherapeutics was a new Yorktown Management & Research Company position in Q2 2026.
Arcutis Biotherapeutics made up 0.26% of Yorktown Management & Research Company's portfolio in Q2 2026, its #148 holding.
63 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.